{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:36:58Z","timestamp":1790519818059,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01-CA168268"],"award-info":[{"award-number":["R01-CA168268"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008349","name":"University of Duisburg-Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00262-019-02348-2","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T07:27:17Z","timestamp":1559028437000},"page":"1133-1141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma"],"prefix":"10.1007","volume":"68","author":[{"given":"Sonja","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Sook","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice M.","family":"Razzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellsye P. L.","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Chelvanambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Storkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa L.","family":"Whiteside","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"2348_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12967-016-0828-6","volume":"14","author":"AW Eckert","year":"2016","unstructured":"Eckert AW et al (2016) Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma. J Transl Med 14:85","journal-title":"J Transl Med"},{"issue":"1","key":"2348_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2982","volume":"11","author":"CR Leemans","year":"2011","unstructured":"Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9\u201322","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2348_CR3","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386","journal-title":"Int J Cancer"},{"issue":"1","key":"2348_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/1078-0432.CCR-17-1261","volume":"24","author":"TL Whiteside","year":"2018","unstructured":"Whiteside TL (2018) Head and neck carcinoma immunotherapy: facts and hopes. Clin Cancer Res 24(1):6\u201313","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2348_CR5","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1158\/1078-0432.CCR-18-0408","volume":"24","author":"I Melero","year":"2018","unstructured":"Melero I et al (2018) Introducing a new series: immunotherapy facts and hopes. Clin Cancer Res 24(8):1773\u20131774","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2348_CR6","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/annonc\/mdw226","volume":"27","author":"P Economopoulou","year":"2016","unstructured":"Economopoulou P et al (2016) The promise of immunotherapy in head and neck squamous cell carcinoma. Ann Oncol 27(9):1675\u20131685","journal-title":"Ann Oncol"},{"issue":"24","key":"2348_CR7","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1158\/0008-5472.CAN-13-3583","volume":"74","author":"C Cekic","year":"2014","unstructured":"Cekic C et al (2014) Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res 74(24):7250\u20137259","journal-title":"Cancer Res"},{"issue":"19","key":"2348_CR8","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867","journal-title":"N Engl J Med"},{"issue":"36","key":"2348_CR9","doi-asserted-by":"publisher","first-page":"27571","DOI":"10.1074\/jbc.M110.127100","volume":"285","author":"M Mandapathil","year":"2010","unstructured":"Mandapathil M et al (2010) Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 285(36):27571\u201327580","journal-title":"J Biol Chem"},{"issue":"3","key":"2348_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/onc.2016.206","volume":"36","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36(3):293\u2013303","journal-title":"Oncogene"},{"issue":"7","key":"2348_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.neo.2017.02.004","volume":"19","author":"M Mediavilla-Varela","year":"2017","unstructured":"Mediavilla-Varela M et al (2017) A novel antagonist of the immune checkpoint protein adenosine A2a receptor restores tumor-infiltrating lymphocyte activity in the context of the tumor microenvironment. Neoplasia 19(7):530\u2013536","journal-title":"Neoplasia"},{"issue":"3","key":"2348_CR12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4049\/jimmunol.154.3.1041","volume":"154","author":"EJ Goetzl","year":"1995","unstructured":"Goetzl EJ, An S, Zeng L (1995) Specific suppression by prostaglandin E2 of activation-induced apoptosis of human CD4+CD8+ T lymphoblasts. J Immunol 154(3):1041\u20131047","journal-title":"J Immunol"},{"key":"2348_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/ITT.S55415","volume":"4","author":"TL Whiteside","year":"2015","unstructured":"Whiteside TL (2015) The role of regulatory T cells in cancer immunology. Immunotargets Ther 4:159\u2013171","journal-title":"Immunotargets Ther"},{"issue":"1","key":"2348_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","volume":"6","author":"RD Leone","year":"2018","unstructured":"Leone RD, Emens LA (2018) Targeting adenosine for cancer immunotherapy. J Immunother Cancer 6(1):57","journal-title":"J Immunother Cancer"},{"issue":"11","key":"2348_CR15","first-page":"622","volume":"12","author":"L Hutchinson","year":"2015","unstructured":"Hutchinson L (2015) Immunotherapy: evading immune escape: synergy of COX and immune-checkpoint inhibitors. Nat Rev Clin Oncol 12(11):622","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2348_CR16","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","volume":"3","author":"PA Beavis","year":"2015","unstructured":"Beavis PA et al (2015) Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res 3(5):506\u2013517","journal-title":"Cancer Immunol Res"},{"key":"2348_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","volume":"9","author":"A Durgeau","year":"2018","unstructured":"Durgeau A et al (2018) Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. Front Immunol 9:14","journal-title":"Front Immunol"},{"issue":"2","key":"2348_CR18","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1182\/blood-2005-07-2737","volume":"107","author":"G Zhou","year":"2006","unstructured":"Zhou G, Drake CG, Levitsky HI (2006) Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107(2):628\u2013636","journal-title":"Blood"},{"issue":"1","key":"2348_CR19","doi-asserted-by":"publisher","first-page":"8322","DOI":"10.1038\/s41598-017-08665-9","volume":"7","author":"RC Mould","year":"2017","unstructured":"Mould RC et al (2017) Enhancing immune responses to cancer vaccines using multi-site injections. Sci Rep 7(1):8322","journal-title":"Sci Rep"},{"issue":"6","key":"2348_CR20","doi-asserted-by":"publisher","first-page":"e1315487","DOI":"10.1080\/2162402X.2017.1315487","volume":"6","author":"Z Liu","year":"2017","unstructured":"Liu Z et al (2017) Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4(+) T cells combined with agonist alpha-GITR mAb promotes durable CD8(+) T-cell-dependent antitumor immunity. Oncoimmunology 6(6):e1315487","journal-title":"Oncoimmunology"},{"issue":"3","key":"2348_CR21","doi-asserted-by":"publisher","first-page":"101042831769502","DOI":"10.1177\/1010428317695021","volume":"39","author":"S Arab","year":"2017","unstructured":"Arab S et al (2017) Increased efficacy of a dendritic cell-based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor. Tumour Biol 39(3):1010428317695021","journal-title":"Tumour Biol"},{"key":"2348_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.csbj.2015.03.008","volume":"13","author":"RD Leone","year":"2015","unstructured":"Leone RD, Lo YC, Powell JD (2015) A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J 13:265\u2013272","journal-title":"Comput Struct Biotechnol J"},{"issue":"5","key":"2348_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/hed.2880160506","volume":"16","author":"BL Hawkins","year":"1994","unstructured":"Hawkins BL et al (1994) 4NQO carcinogenesis: a mouse model of oral cavity squamous cell carcinoma. Head Neck 16(5):424\u2013432","journal-title":"Head Neck"},{"issue":"3","key":"2348_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10735-009-9228-z","volume":"40","author":"RA Schoop","year":"2009","unstructured":"Schoop RA, Noteborn MH, BaatenburgdeJong RJ (2009) A mouse model for oral squamous cell carcinoma. J Mol Histol 40(3):177\u2013181","journal-title":"J Mol Histol"},{"issue":"4","key":"2348_CR25","first-page":"473","volume":"27","author":"Z Yang","year":"2013","unstructured":"Yang Z et al (2013) Comparable molecular alterations in 4-nitroquinoline 1-oxide-induced oral and esophageal cancer in mice and in human esophageal cancer, associated with poor prognosis of patients. Vivo 27(4):473\u2013484","journal-title":"Vivo"},{"issue":"3","key":"2348_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/BF00300234","volume":"24","author":"MM Tomayko","year":"1989","unstructured":"Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24(3):148\u2013154","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2348_CR27","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.4049\/jimmunol.1001294","volume":"185","author":"Y Qu","year":"2010","unstructured":"Qu Y et al (2010) Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. J Immunol 185(5):2895\u20132902","journal-title":"J Immunol"},{"issue":"19","key":"2348_CR28","doi-asserted-by":"publisher","first-page":"8076","DOI":"10.1158\/0008-5472.CAN-08-0387","volume":"68","author":"H Komita","year":"2008","unstructured":"Komita H et al (2008) CD8\u2009+\u2009T-cell responses against hemoglobin-beta prevent solid tumor growth. Cancer Res 68(19):8076\u20138084","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"2348_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0022-1759(02)00013-3","volume":"262","author":"YI Son","year":"2002","unstructured":"Son YI et al (2002) A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J Immunol Methods 262(1\u20132):145\u2013157","journal-title":"J Immunol Methods"},{"issue":"4","key":"2348_CR30","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.4049\/jimmunol.1101644","volume":"188","author":"X Zhao","year":"2012","unstructured":"Zhao X et al (2012) Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol 188(4):1782\u20131788","journal-title":"J Immunol"},{"issue":"2","key":"2348_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-017-2079-7","volume":"67","author":"Q Liu","year":"2018","unstructured":"Liu Q et al (2018) BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. Cancer Immunol Immunother 67(2):299\u2013310","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2348_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1479-5876-2-40","volume":"2","author":"M Hatano","year":"2004","unstructured":"Hatano M et al (2004) Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med 2(1):40","journal-title":"J Transl Med"},{"issue":"8","key":"2348_CR33","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1054\/bjoc.2000.1715","volume":"84","author":"Y Umano","year":"2001","unstructured":"Umano Y et al (2001) Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 84(8):1052\u20131057","journal-title":"Br J Cancer"},{"issue":"11","key":"2348_CR34","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1002\/eji.1830261114","volume":"26","author":"V Lacabanne","year":"1996","unstructured":"Lacabanne V et al (1996) A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur J Immunol 26(11):2635\u20132639","journal-title":"Eur J Immunol"},{"issue":"5","key":"2348_CR35","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/eji.200839098","volume":"39","author":"UB Hofmann","year":"2009","unstructured":"Hofmann UB et al (2009) Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes. Eur J Immunol 39(5):1419\u20131424","journal-title":"Eur J Immunol"},{"issue":"1","key":"2348_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/01.cji.0000175494.13476.56","volume":"29","author":"Y Dong","year":"2006","unstructured":"Dong Y et al (2006) Identification of H-2Db-specific CD8\u2009+\u2009T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J Immunother 29(1):32\u201340","journal-title":"J Immunother"},{"issue":"6","key":"2348_CR37","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00262-011-1155-7","volume":"61","author":"AT Waickman","year":"2012","unstructured":"Waickman AT et al (2012) Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother 61(6):917\u2013926","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2348_CR38","doi-asserted-by":"publisher","first-page":"e1290035","DOI":"10.1080\/2162402X.2017.1290035","volume":"6","author":"KP Fabian","year":"2017","unstructured":"Fabian KP et al (2017) Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice. Oncoimmunology 6(3):e1290035","journal-title":"Oncoimmunology"},{"issue":"4","key":"2348_CR39","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","volume":"24","author":"MN Theodoraki","year":"2018","unstructured":"Theodoraki MN et al (2018) Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients. Clin Cancer Res 24(4):896\u2013905","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2348_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/hed.24595","volume":"39","author":"WC Chen","year":"2017","unstructured":"Chen WC et al (2017) Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck. Head Neck 39(2):347\u2013355","journal-title":"Head Neck"},{"issue":"1","key":"2348_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1601-0825.2011.01846.x","volume":"18","author":"M Chu","year":"2012","unstructured":"Chu M et al (2012) Myeloid-derived suppressor cells contribute to oral cancer progression in 4NQO-treated mice. Oral Dis 18(1):67\u201373","journal-title":"Oral Dis"},{"key":"2348_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.oraloncology.2016.05.012","volume":"59","author":"H Fuse","year":"2016","unstructured":"Fuse H et al (2016) Enhanced expression of PD-L1 in oral squamous cell carcinoma-derived CD11b(+)Gr-1(+) cells and its contribution to immunosuppressive activity. Oral Oncol 59:20\u201329","journal-title":"Oral Oncol"},{"issue":"5","key":"2348_CR43","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/sj.bjc.6602407","volume":"92","author":"C Schaefer","year":"2005","unstructured":"Schaefer C et al (2005) Characteristics of CD4\u2009+\u2009CD25\u2009+\u2009regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92(5):913\u2013920","journal-title":"Br J Cancer"},{"issue":"20","key":"2348_CR44","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.1158\/1078-0432.CCR-09-1143","volume":"15","author":"M Mandapathil","year":"2009","unstructured":"Mandapathil M et al (2009) Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 15(20):6348\u20136357","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2348_CR45","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/bjc.2013.645","volume":"109","author":"HB Jie","year":"2013","unstructured":"Jie HB et al (2013) Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 109(10):2629\u20132635","journal-title":"Br J Cancer"},{"issue":"3","key":"2348_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/cei.13113","volume":"192","author":"MN Theodoraki","year":"2018","unstructured":"Theodoraki MN, Hoffmann TK, Whiteside TL (2018) Separation of plasma-derived exosomes into CD3((+)) and CD3((\u2212)) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients. Clin Exp Immunol 192(3):271\u2013283","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"2348_CR47","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/mc.22767","volume":"57","author":"JF Liu","year":"2018","unstructured":"Liu JF et al (2018) Inhibition of JAK2\/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer. Mol Carcinog 57(3):429\u2013439","journal-title":"Mol Carcinog"},{"issue":"3","key":"2348_CR48","doi-asserted-by":"publisher","first-page":"e58397","DOI":"10.1371\/journal.pone.0058397","volume":"8","author":"L Wang","year":"2013","unstructured":"Wang L et al (2013) Graft-versus-host disease is enhanced by selective CD73 blockade in mice. PLoS One 8(3):e58397","journal-title":"PLoS One"},{"issue":"2","key":"2348_CR49","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/cei.12354","volume":"177","author":"PJ Schuler","year":"2014","unstructured":"Schuler PJ et al (2014) Human CD4\u2009+\u2009CD39\u2009+\u2009regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73\u2009+\u2009exosomes or CD73\u2009+\u2009cells. Clin Exp Immunol 177(2):531\u2013543","journal-title":"Clin Exp Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02348-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02348-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02348-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T23:16:23Z","timestamp":1694906183000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02348-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["2348"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02348-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"9 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) at the University of Pittsburgh and the Hillman Cancer Center (IACUC protocol # 16088780).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Female 6-week-old C57BL\/6 WT mice were purchased from The Jackson Laboratory, Bar Harbor, ME, USA and were housed under pathogen-free conditions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal source"}},{"value":"No cell lines were used. DC.IL-12 cells are murine DCs isolated from the bone marrow, cultured and infected with recombinant adenovirus encoding mIL-12p70.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}